K–M analysis showed that the low-expression group with lower expression levels of NDUFB8, NDUFA6, COX5B, COX6C, and USMG5 had significantly better survival than those with higher expression levels (Figure 6B), indicating that NDUFB8, NDUFA6, COX5B, COX6C, and USMG5 may act as candidate prognostic biomarkers in MM. Here, NDUFA6 is linked to Miyoshi myopathy.